Summary

Eligibility
for people ages 6-39 (full criteria)
Location
at UCSF
Dates
study started
completion around
Principal Investigator
by Jennifer G. Michlitsch (ucsf)Arun A. Rangaswami (ucsf)
Headshot of Jennifer G. Michlitsch
Jennifer G. Michlitsch
Headshot of Arun A. Rangaswami
Arun A. Rangaswami

Description

Summary

This study attempts to learn more about the health of persons with Down syndrome after treatment for acute leukemia. Children with Down syndrome are at increased risk for side effects during treatment for acute leukemia, but it is unclear of their risk for long-term effects of cancer treatment. By learning more about the factors that may contribute to chronic health conditions and long-term effects after treatment for leukemia in persons with Down syndrome, clinical practice guidelines for survivorship care can be developed to help improve their quality-of-life.

Official Title

Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)

Details

Keywords

B Acute Lymphoblastic Leukemia Associated With Down Syndrome, Down Syndrome, Myeloid Leukemia Associated With Down Syndrome, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Syndrome, Biospecimen Collection, Clinical Evaluation, Neurocognitive Assessment

Eligibility

Locations

  • UCSF Benioff Children's Hospital Oakland accepting new patients
    Oakland California 94609 United States
  • UCSF Medical Center-Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Valley Children's Hospital accepting new patients
    Madera California 93636 United States

Lead Scientists at University of California Health

  • Jennifer G. Michlitsch (ucsf)
    Professor, Pediatrics, School of Medicine. Authored (or co-authored) 23 research publications
  • Arun A. Rangaswami (ucsf)
    I am one of the senior solid tumor faculty at UCSF, having joined the institution in 2019. My scholarly and clinical practice have focused on the treatment of pediatric liver cancers and rare cancers.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's Oncology Group
ID
NCT05702645
Study Type
Observational
Participants
Expecting 330 study participants
Last Updated